IP Library Granted Patent US 9,492,351
Granted Patent B2
US 9,492,351 · App. 13/295,408 · Granted Nov 15, 2016

Apparatus and methods for sequestering fluids exhausted during fluid transfer

Inventors: Matthew J. Stepovich (Santa Cruz, CA); Randy Kesten (Los Altos, CA); Jeff Zalewski (San Francisco, CA)
Assignee: ONPHARMA, INC.
A61J1/2075A61J1/2089A61J1/062A61J1/2017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,492,351
App. No.
13/295,408
Granted
Nov 15, 2016
Kind
B2
Abstract

A liquid transfer connector comprises an enclosure holding a transfer needle and an exhaust needle. A container of donor liquid may be attached to an inlet end of the transfer needle and a container holding a recipient liquid may be attached to an outlet end of the transfer needle and an inlet end of an exhaust needle. The exhaust needle has an outlet end within the connector which releases displaced fluid into an absorbent mass which sequesters the fluid to prevent leakage.

Claims (29)

1. A liquid transfer connector for providing a liquid transfer path between a donor container having a needle-penetrable septum and a recipient container having a needle-penetrable septum, said connector comprising:

an enclosure having an interior chamber with a vent;

a transfer needle having an inlet end extending from one side of the interior chamber and an outlet end extending from another side of the interior chamber, wherein both the inlet end and the outlet end are capable of penetrating a septum on a liquid container;

an exhaust needle having an inlet end adjacent to the outlet end of the transfer needle and an outlet end in the interior chamber; and

a liquid-absorptive mass within the interior chamber, said liquid-absorptive mass adapted for rapid absorption of liquid entering the interior chamber through the exhaust needle.

2. A connector as in claim 1 , wherein the liquid-absorptive mass is at least partially formed from a liquid-absorptive foam.

3. A connector as in claim 2 , wherein the liquid-absorptive foam has an absorptive rate less than 10 seconds as measured by IS09073-6-2000.

4. A connector as in claim 3 , wherein the liquid-absorptive foam comprises a polyvinyl acetal resin.

5. A connector as in claim 1 , wherein the liquid-absorptive mass comprises a block of absorptive material having an interior void which surrounds the outlet end of the exhaust needle.

6. A connector as in claim 5 , wherein the outlet end of the exhaust needle is spaced apart from walls of the interior void so that the exhausted recipient liquid can pool in the void without submerging the inlet end.

7. A connector as in claim 1 , wherein the liquid-absorptive mass comprises absorbent beads having a size or shape which prevents passage through the vents.

8. A connector as in claim 7 , wherein the absorbent beads are loose and fill the interior chamber.

9. A connector as in claim 1 , wherein the enclosure comprises a cylindrical sleeve having a partition which separates an attachment receptacle that encloses the outlet end of the transfer needle and the inlet end of the exhaust needle from the interior chamber.

10. A connector as in claim 1 , wherein the transfer needle passes axially through the liquid-absorptive mass.

11. A method for transferring a donor liquid into a recipient liquid present in a closed container, said method comprising:

establishing a transfer flow path from a source of the donor liquid into the closed container filled with the recipient liquid;

establishing an exhaust flow path from the closed container to an absorbent mass; and

causing a volume of the donor liquid to flow into the closed container through the transfer flow path which in turn causes a like volume of the recipient liquid to flow through the exhaust flow path into the absorbent mass, wherein the entire volume of the exhausted recipient liquid is absorbed by the absorbent mass.

12. A method as in claim 11 , wherein the absorbent mass is at least partially formed from a liquid-absorptive foam.

13. A method as in claim 12 , wherein the liquid-absorptive foam has an absorptive rate less than 10 seconds as measured by IS09073-6-2000.

14. A method as in claim 13 , wherein the liquid-absorptive foam comprises a polyvinyl acetal resin.

15. A method as in claim 11 , wherein the absorbent mass comprises absorbent beads having a size or shape which prevents passage through the vents.

16. A method as in claim 15 , wherein the absorbent beads are loose and fill the interior chamber.

17. A method as in claim 11 , wherein the absorbent mass comprises a block of absorptive material having an interior void which surrounds an outlet end of the exhaust needle.

18. A method as in claim 11 , wherein the absorbent mass has an absorptive capacity equal to at least twice the volume of the donor liquid.

19. A method as in claim 17 , wherein the interior void has a volume equal to at least the volume of the donor liquid.

20. A method as in claim 17 , wherein the outlet end of the exhaust needle is spaced apart from walls of the interior void so that the exhausted recipient liquid can pool in the interior void without submerging the outlet end.

21. A method as in claim 11 , wherein the absorbent mass comprises a material that does not biologically or chemically react with the recipient liquid.

22. A connector as in claim 1 , wherein the liquid-absorptive mass comprises a material that does not biologically or chemically react with the recipient liquid.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2018
From: ONPHARMA INC.
To: ONPHARMA COMPANY
Reel/Frame 046063/0392 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: ONPHARMA INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0777 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Dec 3, 2014
From: ONPHARMA INC
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 034524/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2012
From: STEPOVICH, MATTHEW J.; KESTEN, RANDY; ZALEWSKI, JEFF
To: ONPHARMA, INC.
Reel/Frame 027908/0369 →
Continuity (2)
Provisional Application 61458002 · Nov 15, 2010
Related Publication 20120291909A1 · Nov 22, 2012